Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in the first-line setting: Results from the IMPACT RCC Real-World Study

Abstract BACKGROUND: A key therapeutic goal of metastatic renal cell carcinoma (mRCC) treatment is delayed disease progression. The degree to which early therapeutic success affects downstream outcomes is not well established. OBJECTIVE: To assess the...

Real-world outcomes among US Veterans Health Administration patients newly diagnosed with metastatic renal cell carcinoma and treated with first-line monotherapy

Abstract Introduction: Substantial unmet needs exist among patients with metastatic renal cell carcinoma (mRCC). This retrospective study evaluated treatment patterns as well as clinical and economic outcomes associated with first-line monotherapy among patients with...